Clorotekal is owned by B Braun Medical Inc.
Clorotekal contains Chloroprocaine Hydrochloride.
Clorotekal has a total of 2 drug patents out of which 0 drug patents have expired.
Clorotekal was authorised for market use on 26 September, 2017.
Clorotekal is available in solution;intrathecal dosage forms.
Clorotekal can be used as a method for inducing a regional anaesthesia via intrathecal administration of a patented preservative free solution for injection (with a specific composition, ph, osmolality and density) containing 9-11 mg/ml chloroprocaine hcl.
The generics of Clorotekal are possible to be released after 11 December, 2033.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8969412||B BRAUN MEDICAL INC||Use for a composition comprising chloroprocaine HCL, a new composition comprising chloroprocaine HCL and a method for its manufacture|| |
(3 years from now)
|US9504666||B BRAUN MEDICAL INC||Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration|| |
(10 years from now)
Market Authorisation Date: 26 September, 2017
Treatment: A method for inducing a regional anaesthesia via intrathecal administration of a patented preservative free solution for injection (with a specific composition, ph, osmolality and density) containing 9-11 mg/ml chloroprocaine hcl
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic